Allogene Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 18, 2025, details the results of Allogene Therapeutics, Inc.'s 2025 Annual Meeting of Stockholders. The record date for the meeting was April 22, 2025, with 218,705,245 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Proposal 1: Election of Directors - Stockholders elected three Class I Directors to serve until the 2028 Annual Meeting.
- Elizabeth Barrett: 131,435,760 votes For; 25,929,654 votes Withheld.
- Arie Belldegrun, M.D.: 150,891,245 votes For; 6,474,169 votes Withheld.
- David Chang, M.D., Ph.D.: 153,721,017 votes For; 3,644,397 votes Withheld.
- Proposal 2: Advisory Vote on Executive Compensation - Stockholders approved the compensation of Named Executive Officers.
- 139,947,868 votes For; 14,233,309 votes Against; 3,184,237 Abstentions.
- Proposal 3: Ratification of Independent Auditor - Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- 190,111,256 votes For; 414,604 votes Against; 351,588 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the three newly elected Class I Directors and their tenure until 2028.
- Verification of the significant vote count for the ratification of Ernst & Young LLP.
- Review of the proxy statement for details on the executive compensation package approved by stockholders.
- Confirmation of the total shares outstanding (218,705,245) as of the April 22, 2025 record date.